Expected incidence of tardive dyskinesia associated with atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 4, 2000, Pages 21-26

  Glazer, William M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; DRUG EFFECT; FOLLOW UP; HUMAN; INCIDENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; HUMANS; INCIDENCE; MOLINDONE; PIRENZEPINE; PROSPECTIVE STUDIES; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL ANALYSIS;

EID: 0034097416     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Owens DG, Johnstone EC. The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. Br J Psychiatry 1980;136:384-395
2. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement. Arch Gen Psychiatry 1982;39:452-461
3. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 1990;3:315-320
4. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254-258
5. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
6. Tamminga CA, Thaker GK, Moran M. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994:55 (9, suppl B):102-106
7. Dalack GW, Becks L, Meador-Woodruff JH. Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22:567-573
8. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13: 25-40
9. Meco G, Bedini L, Bonifati V, et al. Risperidone in the treatment of chronic-schizophrenia with tardive dyskinesia. Curr Ther Res 1989;46:876-883
10. Kinon BJ, Basson BR, Stauffer VL, et al. Effect of chronic olanzapine treatment on the course of presumptive tardive dyskinesia. Presented at the 37th Annual Meeting of the American College of Neuropsychopharmacology: Dec 14-18, 1998; San Juan, Puerto Rico
11. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine [letter]. Arch Gen Psychiatry 1998;55:279-280
12. O'Brien J, Barber R. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject [letter]. Br J Psychiatry 1998;172:186
13. Almeida OP. Olanzapine for the treatment of tardive dyskinesia [letter]. J Clin Psychiatry 1998;59:380-381
14. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-330
15. Woerner MG, Sheitman BB, Lieberman JA, et al. Tardive dyskinesia induced by risperidone [letter]? Am J Psychiatry 1996;153:843
16. Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report [letter]. J Clin Psychiatry 1995;56:484-485
17. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997;12:119-121
18. Silberbauer C. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 1998;31:68-69
19. Saran BM. Risperidone-induced tardive dyskinesia [letter]. J Clin Psychiatry 1998;59:29-30
20. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61 (suppl 4):27-32
21. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719
22. Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone [letter]. J Clin Psychiatry 1999;60:485-487
23. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine [letter]. Am J Psychiatry 1999;156:798-799
24. Bymaster F, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic agent olanzapine. Neuropsychopharmacology 1996;14:87-96
25. Beasley CM Jr, Dellva MA, Tamura RN, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30
26. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154: 1248-1254
27. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
28. Beasley CM Jr. Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137
29. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
30. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993;50: 723-733
31. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982;39:486-487